フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
IRVINE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical development company...
FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM) IRVINE, Calif., Jan. 19...
Thomas Stankovich, Former Vice President and Chief Financial Officer of MP Biomedicals, Ribapharm and ICN / Valeant Pharmaceuticals Joins Cobalis...
European Patent Office Allows New Patent for PreHistin(TM) -- 'Cyanocobalamin Treatment in Allergic Disease' IRVINE, Calif., Nov. 2...
Safe, Non-Drowsy PreHistin(TM) Achieves Clinical and Statistical Significance (p= 0.0028) Versus Placebo; Study Demonstrates Dramatic Reduction in...
IRVINE, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC:CLSC) (BULLETIN BOARD: CLSC) , a pharmaceutical biotech company...
Cobalis Corp. Phase III Trial for PreHistin(TM) Shows Positive Results for Pre-Seasonal Treatment to Mitigate Allergy Symptoms in Humans IRVINE...
Nasdaq Notifies Cobalis That It Will Remove 'V' From Its Stock Symbol -- an Update on Mandatory Share Certificate Exchange IRVINE, Calif., Oct...
Cobalis Changes Its Trading Symbol From "CBSC" to "CLSC" - Update on Mandatory Share Certificate Exchange IRVINE, Calif., Aug. 27...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約